20 results about "Glycopyrrolate" patented technology

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

Provided in the present invention are a suspended triple inhalation aerosol composition and a preparation method therefor. The aerosol composition comprises fluticasone furoate, vilanterol trifenatate, glycopyrrolate, a diluent, a surfactant and a propellant; has higher drug-delivery efficiency and drug-delivery dose, and higher lung deposition; and has the effects of better ameliorating Mch-induced elevated pulmonary resistance and decreased pulmonary compliance, thereby facilitating improvement to medication safety and patient compliance.

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

A method and formulation is disclosed for making a pharmaceutical composition for pulmonary administration comprising co-jet milling glycopyrrolate and magnesium stearate, wherein the co-jet milled glycopyrrolate and magnesium stearate is then subjected to a conditioning step which includes exposure of the co-jet milled glycopyrrolate and magnesium stearate to humidity.

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis. 20 24 22 77 14 29 O ct 2 02 4 A B S T R A C T 2 0 2 4 2 2 7 7 1 4 2 9 O c t 2 0 2 4

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) glycopyrrolate; and (iii) a diluent, which diluent comprises water, wherein: the glycopyrrolate is dissolved in the diluent; the concentration of glycopyrrolate is less than or equal to 5.0 mg / mL; and the pH of the liquid pharmaceutical composition is from 3.0 to 6.0. The invention also relates to a nebuliser comprising the liquid pharmaceutical composition.

A pharmaceutical composition is described. The composition comprises a drug component consisting of at least one indacaterol compound selected from indacaterol and indacaterol maleate, and at least one pharmaceutically acceptable salt of glycopyrrolate; and a propellant component at least 90 weight % of which is 1,1-difluoroethane (HFA-152a).

The present application relates to an inhalable liquid composition suitable for nebulization comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide for treating a pulmonary disorder(s). The present application also relates to a process for preparing such a composition comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide.

The invention provides a surface anesthetic with oral mucosa adhesiveness and salivation resistance and a preparation method of the surface anesthetic, and belongs to the technical field of anesthetics. The surface anesthetic provided by the invention comprises lidocaine hydrochloride, glycopyrronium bromide and an auxiliary material, and the auxiliary material comprises a drug entrapment auxiliary material. Compared with caine anesthetics used clinically, the surface anesthetic provided by the invention has multiple functions of salivation resistance, good mucous membrane adhesiveness and improved taste, not only improves the drug effect, but also increases the medication compliance, and has great clinical application value.

Individually packaged topical formulations comprising about 0.25 to about 6% w / w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer.

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

The invention provides a surface anesthetic with oral mucosa adhesiveness, salivation resistance and taste improvement effects and a preparation method of the surface anesthetic, and belongs to the technical field of anesthetics. The surface anesthetic provided by the invention comprises tetracaine hydrochloride, glycopyrronium bromide and an auxiliary material, and the auxiliary material comprises a drug entrapment auxiliary material. Compared with caine anesthetics used clinically, the surface anesthetic provided by the invention has multiple functions of salivation resistance, good mucous membrane adhesiveness and improved taste, not only improves the drug effect, but also increases the medication compliance, and has great clinical application value.

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

A pharmaceutical composition comprises a drug component. The drug component is a combination of one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone dipropionate, and one long acting beta-2-agonist (LABA) selected from formoterol and pharmaceutically acceptable salts thereof. The pharmaceutical composition also comprises a propellant component. The propellant component is at least 90 weight percent 1,1-difluoroethane (HFA-152a). The pharmaceutical composition is in the form of a solution and optionally comprises ethanol, but is free of other polar solvents / co-solvents. The drug component is the sole drug component in the pharmaceutical composition.

Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.